1.Comparison of total hip arthroplasty and hemiarthroplasty in treating fracture of femoral neck in elderly patients
Wanzhi GAO ; Kuoye MEN ; Jianhua SHAO
Chinese Journal of Primary Medicine and Pharmacy 2012;19(12):1783-1784
Objective To compare the operation and clinical effects of total hip arthroplasty and hemiarthroplasty in the treatment of fracture of femoral neck in elderly patients.Methods 58 elderly patients( ≥85 ) with femoral neck fracture were divided into observation group(n=39) and control group(n=19).The observation group was treated by hemiarthroplasty and the control group was treated by total hip arthroplasty.The operation time,blood loss,hospital stay,postoperative hip functional score and complications were observed and compared between the two groups.Results The operation time and blood loss of the observation group were(71.6 ±9.3)min and (266.8±113.5) ml respectively,which were significantly less than those of the control group ( t=7.89,3.43,all P < 0.05 ).Therer was no significant difference of the hospital stay,postoperative hip functional score and incidence rate of complications between the two groups.Conclusion Hemiarthroplasty was an ideal rmethod in treating fracture of femoral neck in elderly patients,which was effective and simple.
2. Analysis of clinicopathological features of patients with simple breast cancer and breast cancer with thyroid cancer
Haibo YANG ; Jinnan GAO ; Wanzhi SONG
Chinese Journal of Oncology 2019;41(8):624-627
Objective:
To investigate the relationship between breast cancer and thyroid cancer.
Methods:
A cohort of 747 female patients with stage Ⅰ-Ⅲ invasive breast cancer were enrolled in this retrospective study. The differences of clinical and pathological data were compared between the simple breast cancer group (723 cases) and the breast cancer with thyroid cancer group (24 cases), to analyze the relevant factors of second primary thyroid cancer in patients with breast cancer.
Results:
There were significant differences in the menstrual status and estrogen receptor (ER) status between the group of patients with breast cancer only and breast cancer patients with secondary primary thyroid cancer (